NASDAQ: AXDX - Accelerate Diagnostics, Inc.

Rentabilität für sechs Monate: +115.6%
Sektor: Healthcare

Aktionsplan Accelerate Diagnostics, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Weitere Details
It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

Выручка 0.0093
EBITDA -0.0674
Число акций ао 0.01248 млрд
P/S 99.84
P/BV -125.79
EV/EBITDA -14.85
Цена ао 0.9603
ISIN US00430H1023
Сайт https://acceleratediagnostics.com
Валюта usd
IPO date 1996-11-18
Sector Health Care
Industry Life Sciences Tools & Services
Валюта отчета usd
Preisänderung pro Tag: -0.9626% (1.87)
Preisänderung pro Woche: +1.2% (1.83)
Preisänderung pro Monat: +21.84% (1.52)
Preisänderung über 3 Monate: +63.89% (1.13)
Preisänderung über sechs Monate: +115.6% (0.859)
Preisänderung pro Jahr: -67.79% (5.75)
Preisänderung über 3 Jahre: -66.51% (5.53)
Preisänderung über 5 Jahre: -91.1% (20.82)
Preisänderung seit Jahresbeginn: -60.09% (4.64)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 4.48 4
P/BV -2.72 0
P/E 0 0
EV/EBITDA -1.6 0
Gesamt: 4.25

Effizienz

Name Bedeutung Grad
ROA, % -196.45 0
ROE, % 309.83 10
Gesamt: 3.33

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.7561 10
Gesamt: 9.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 29.67 4
Rentabilität Ebitda, % -24.67 0
Rentabilität EPS, % -68.08 0
Gesamt: 0.8
Weitere Details

Institutionen Volumen Aktie, %
Griffin Asset Management, Inc. 1219724 5.63
Vanguard Group Inc 306637 1.42
Birchview Capital, LP 225239 1.04
Cannell (Peter B.) & Company Inc 114690 0.53
Oracle Investment Management Inc 111575 0.52
Geode Capital Management, LLC 87003 0.4
Chartist, Inc. 68996 0.32
TCI Wealth Advisors, Inc. 58680 0.27
Blackrock Inc. 50842 0.23
Northern Trust Corporation 46119 0.21



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Jack Phillips CEO, President & Director 595k 1966 (58 Jahre)
Mr. Lawrence Michael Mertz Chief Technology Officer 335.94k 1963 (61 Jahr)
Mr. David Patience Chief Financial Officer 285.27k 1986 (38 Jahre)
Ms. Maya Gowri Senior VP & Head of Operations N/A
Laura Pierson Investor Relations Officer N/A
Mr. John Meduri Chief Strategy Officer N/A
Mr. Chris Thode Senior Vice President of US Commercial N/A
Ms. Rita Boukamel Senior VP & Head of EMEA N/A

Adresse: United States, Tucson. AZ, 3950 South Country Club Road - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://acceleratediagnostics.com